Office of Commercialization  Neutrophil Apoptosis induced by Nanoparticles Improved the Therapies of Inflammatory Diseases
Neutrophil Apoptosis induced by Nanoparticles Improved the Therapies of Inflammatory Diseases

Neutrophil Apoptosis induced by Nanoparticles Improved the Therapies of Inflammatory Diseases

Description:

Unmet Need: Improved specific induction of neutrophil apoptosis through the use of nanoparticles to treat inflammatory diseases.

Systemic inflammatory responses are a normal response to infections and tissue damage. However, when the expression of inflammatory cells is uncontrolled associated diseases occur. Through specific targeting of neutrophil by the current technology a return to homeostatic levels of neutrophils can be accomplished. This neutrophil apoptosis inducing drug however, does not suppress the entire immune system, allowing for patients to return to normal inflammatory levels.

The Technology: Nanoparticle delivery of a drug to induce neutrophil apoptosis decreasing inflammatory diseases.

The inventors have developed a method for delivering a drug with pH selectivity wherein the drug specifically targets neutrophil and induces apoptosis. Through the selective targeting of neutrophils, a decrease in inflammatory responses can be accomplished which allows for the  treatment of immune diseases such as sepsis. The drug’s specificity and nanoparticle delivery ensure there is not a suppression of the systemic immune system.

Applications:

  • Treatment of neutrophil-induced inflammation
  • Nanoparticle delivery of drugs
  • pH specific drug release mechanism
  • Treatment of sepsis

Advantages:

  • Targeted apoptosis of neutrophils
  • Specificity of drug delivery
  • Decreased active drug needed due to targeted delivery
  • Treatment of inflammatory responses

 

Patent Information: